Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prunella Oral Liquid in the Treatment of Benign Thyroid Nodules
NCT06423235Phase 4Recruiting
- Sponsor
- Guiyang Xintian Pharmaceutical Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Botanical
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Prunella Oral Liquid in thyroid nodule (4 arms), sponsored by Guiyang Xintian Pharmaceutical Co., Ltd. Primary endpoint: Rate of change in thyroid nodule volume from baseline at 9 months. Started Jul 2024; status: recruiting.
02
Drugs
Prunella Oral Liquid
03
Conditions
thyroid nodule
Beyond the preview
Go deeper on NCT06423235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06423235.